Echothiophate Iodide for the Prevention of Progression of Myopia

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Danbury Eye Physicians & Surgeons, PC
• Treatments: Carboxymethylcellulose Sodium; Echothiophate Iodide; Iodine; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Healthy children between 8-15 years of age

• Documentation of progression of myopia within the 12 months prior to enrollment

• Written informed consent/Assent for the study

Exclusion Criteria:

• Any history of retinopathy of prematurity, glaucoma, cataracts, corneal disease, uveitis, manifest strabismus, nystagmus or ocular trauma

• Any history of unstable asthma, diabetes, or juvenile idiopathic arthritis Asthma must be stable for three months prior to enrollment if utilizing oral or inhaled steroids

• Systemic muscarinic agents, steroids, or anticholinesterase agents.

• Benzalkonium chloride preservative allergy.

• Astigmatism >0.75D

• Anisometropia >1.50D

• Pregnancy or a positive pregnancy test at the screening visit.